Reuters logo
Shire flags existing and new drugs in defence to AbbVie
June 23, 2014 / 11:26 AM / 3 years ago

Shire flags existing and new drugs in defence to AbbVie

LONDON, June 23 (Reuters) - Shire said on Monday it expected to generate annual sales of $7 billion from current products and a further $3 billion from medicines in its pipeline, as it fleshed out a defence strategy for the group.

The London-listed drugmaker is seeking to convince shareholders that a $46 billion takeover offer from U.S. group AbbVie - rejected as inadequate - undervalues the business.

Shire, which said on Friday it was targeting product sales of at least $10 billion by 2020 without giving details, also said that in the medium term it expected sales of $6.5 billion by 2016. (Reporting by Ben Hirschler, Editing by Paul Sandle)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below